The sustained presence of angiotensin II type 1 receptor antagonists prevents and attenuates the development of hypertension, cardiac hypertrophy, oxidative stress, and renal injury in SHR [21]. The gene discussed is AGTR1; the disease is cardiac hypertrophy.